Impulses – Perspectives for Digital Healthcare
How are digital solutions changing the way we deal with medication, health literacy, and entire Patient Journeys?
In our “Impulses” section, we look at current developments in digital healthcare – with a special focus on patient engagement and real-world data as key factors for evidence-based innovation and future-oriented strategies for pharmaceutical companies and health insurances. We will show how new digital approaches at the interface between pharmaceuticals, cost bearers, and healthcare can bring about lasting change in patient care.
We aim to provide insightful and inspiring approaches that support pharmaceutical companies, health insurances, and healthcare experts in actively shaping the future of treatments.
Immerse yourself in new perspectives for connected, evidence-based, and patient-centered healthcare!
Beyond Reach and Clicks
The days of tracking visitors on public patient websites are over. For digital patient engagement projects, it is no longer enough to simply document visits, reach or downloads. What is of particular interest to pharmaceutical companies is how specific patient groups...
Healthy Longevity Starts in Everyday Life: What the Pharmaceutical Industry Should Know About Long-Term Patient Support
When people talk about longevity, the focus is often on new active substances, biomarkers, prevention programs or technological innovations. For many people, however, a long life in good health depends on a less spectacular factor: their daily management of health...
What patients really want to know when managing their medication
Between the doctor’s consultation and everyday treatment “I would have liked more information about my medication” Patient organizations, healthcare researchers, and healthcare institutions have been receiving this feedback for years. This does not mean that there is...
Between promise and responsibility: What makes a good health app
Quality criteria between evidence, data quality, and sustainable patient access Health apps have long been part of strategic initiatives in pharmaceutical companies. Today, the question is no longer whether they are used, but which applications actually provide robust...
Direct-To-Patient (d2p) in the Pharmaceutical Industry: Between Regulatory Boundaries and Strategic Necessity
How can pharmaceutical companies reach patients directly without taking regulatory risks or losing relevance? This question shapes the current discussion around direct-to-patient approaches. While direct patient communication has been established in the USA for...
Guidelines and Real-World Care: Why Evidence-Based Lipid Therapy Often Fails in Everyday Practice
Cardiovascular guidelines are considered the gold standard of evidence-based medicine. The recommendations of the European Society of Cardiology and the European Atherosclerosis Society for lowering LDL cholesterol are clear, differentiated by risk profiles, and...
Gamification in medical knowledge communication: Opportunities for pharma and digital health?
How can complex medical knowledge be communicated in a way that is not only understood, but also applied in everyday life? This question concerns pharmaceutical companies as well as medical affairs teams and providers of digital health solutions. According to the...
From phase III to real-world care: why the patient perspective matters
Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...
Digital Therapy Support as a Source of Reliable Patient Insights
What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...
Rethinking Omnichannel in the Pharmaceutical Industry: Why Patients Must Be Part of the Strategy
Rethinking Omnichannel Pharma Omnichannel strategies are firmly established in the pharmaceutical industry and primarily aim at consistent, personalized communication with physicians. Numerous professional publications describe omnichannel as a further development of...
Curious?
Then follow us on LinkedIn to receive regular updates, insights, and perspectives on Digital Patient Engagement, Real-World Data, and digital transformation in healthcare – on top of our blog articles and with additional insights into current developments and projects.
Here’s a little preview of what you can expect there.
Working Together for Patient-Centered Care – With Real World Data From mediteo
Gerne zeigen wir Ihnen, wie Sie mediteo nutzen können, um Ihre Patientinnen und Patienten auf ihrer Digital Patient Journey zu erreichen und zu unterstützen. In addition, we provide valuable Real-World Data (RWD) that give you deeper insights into the actual behavior and treatment experiences of your patients. Get in touch with us and we will arrange a non-binding appointment.










